. Author manuscript; available in PMC: 2023 Dec 1.

Published in final edited form as: J Heart Lung Transplant. 2022 Aug 28;41(12):1808–1818. doi: 10.1016/j.healun.2022.08.019

Table 5:

Impact of Anticoagulation on QoL by Generalized Estimating Equation Modeling

		SF-12 Physical Component Score Mean Difference (95% CI)	SF-12 Mental Component Score Mean Difference (95% CI)	emPHasis-10 Mean Difference (95% CI)
Overall Cohort (n=1018)	Unadjusted	−1.95 (−3.20 – −0.70)	−1.03 (−2.26 – 0.21)	2.23 (0.73 – 3.73)
Overall Cohort (n=1018)	Adjusted^*	−0.92 (−2.04 – 0.20)	−1.49 (−2.70 – −0.28)	1.74 (0.40 – 3.09)
IPAH/HPAH (n=479)	Unadjusted	−1.34 (−3.11 – 0.44)	−0.70 (−2.39 – 0.99)	1.35 (−0.81 – 3.52)
IPAH/HPAH (n=479)	Adjusted^*	−0.38 (−1.90 – 1.15)	−1.53 (−3.21 – 0.15)	1.45 (−0.46 – 3.35)
CTD-PAH (n=336)	Unadjusted	−2.44 (−4.62 – −0.25)	−1.46 (−3.47 – 0.56)	2.76 (0.30 – 5.22)
CTD-PAH (n=336)	Adjusted^*	−1.32 (−3.32 – 0.69)	−1.92 (−3.92 – 0.07)	2.07 (−0.18 – 4.33)

Adjusted for age, BMI, sex, race/ethnicity, WHO functional class, PAH-targeted therapy, and site volume